{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T02:15:45Z","timestamp":1794881745998,"version":"4.9.1"},"reference-count":53,"publisher":"Informa UK Limited","issue":"15","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Tolmar, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,6,21]]},"DOI":"10.1080\/14796694.2026.2681674","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:37:23Z","timestamp":1781775443000},"page":"1759-1773","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Rucaparib \u2013 drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-3895","authenticated-orcid":false,"given":"Alan Haruo","family":"Bryce","sequence":"first","affiliation":[{"name":"City of Hope Cancer Center Phoenix","place":["Goodyear, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1293-2241","authenticated-orcid":false,"given":"Paige","family":"Nash","sequence":"additional","affiliation":[{"name":"City of Hope Cancer Center Phoenix","place":["Goodyear, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5474-0643","authenticated-orcid":false,"given":"Anne","family":"Roessler","sequence":"additional","affiliation":[{"name":"Tolmar, Inc","place":["Buffalo Grove, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divneet","family":"Mandair","sequence":"additional","affiliation":[{"name":"City of Hope Cancer Center Phoenix","place":["Goodyear, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00029"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603144"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092435"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.1882"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104738"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03270-z"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.534"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.01.003"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003452"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0050"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.02.018"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI132031"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.025"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59122198"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03961-8"},{"key":"e_1_3_6_20_1","unstructured":"FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. U.S. Food & Drug Administration; 2020 [cited 2025 Dec 14]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate"},{"key":"e_1_3_6_21_1","volume-title":"RUBRACA\u00ae (rucaparib) tablets, for oral use [prescribing information]","year":"2025","unstructured":"RUBRACA\u00ae (rucaparib) tablets, for oral use [prescribing information]. United States: pharmaand GmbH; 2025."},{"key":"e_1_3_6_22_1","volume-title":"Rubraca, INN-rucaparib camsylate [Summary of product characteristics]","year":"2022","unstructured":"Rubraca, INN-rucaparib camsylate [Summary of product characteristics]. Vienna, Austria: pharmaand GmbH; 2022."},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2121"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0552"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq509"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-2476"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-2475"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2656-8"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.575"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.36"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00815-2"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04413-7"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2020.1737759"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12600"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.021"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2199"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01035"},{"key":"e_1_3_6_38_1","unstructured":"FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer: US food & drug administration. 2025 [cited 2026 Jan 3]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer"},{"key":"e_1_3_6_39_1","unstructured":"FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer: US food & drug administration. 2025 [cited 2026 Jan 3]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-rucaparib-metastatic-castration-resistant-prostate-cancer"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214676"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.155"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5060"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001109908.15997.76.07"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.3078"},{"key":"e_1_3_6_45_1","volume-title":"LYNPARZA\u00ae (olaparib) tablets, for oral use [prescribing information]","year":"2025","unstructured":"LYNPARZA\u00ae (olaparib) tablets, for oral use [prescribing information]. Wilmington (DE): AstraZeneca; 2025."},{"key":"e_1_3_6_46_1","volume-title":"TALZENNA\u00ae (talazoparib) capsules, for oral use [Prescribing information]","year":"2025","unstructured":"TALZENNA\u00ae (talazoparib) capsules, for oral use [Prescribing information]. New York (NY): Pfizer Inc.; 2025."},{"key":"e_1_3_6_47_1","volume-title":"Society of Urologic Oncology (SUO) Annual Meeting","author":"Piulats JM","year":"2025","unstructured":"Piulats JM, Ryan CJ, Chowdhury S, et al. Efficacy of rucaparib versus physician\u2019s choice in patients with BRCA-mutated metastatic castration-resistant prostate cancer by age: results from the TRITON3 study. In: Society of Urologic Oncology (SUO) Annual Meeting; Phoenix (AZ); 2025 Dec 2\u20135."},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S335962"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-025-00385-1"},{"key":"e_1_3_6_50_1","volume-title":"AKEEGA\u00ae (niraparib and abiraterone acetate) tablets, for oral use [prescribing information]","year":"2025","unstructured":"AKEEGA\u00ae (niraparib and abiraterone acetate) tablets, for oral use [prescribing information]. Horsham (PA): Janssen Biotech, Inc.; 2025."},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01167-6"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30786-1"},{"key":"e_1_3_6_53_1","unstructured":"Inman S. Rucaparib bests physician\u2019s choice for BRCA+ mCRPC: OncLive. 2023 [cited 2026 Apr 29]. Available from: https:\/\/www.onclive.com\/view\/rucaparib-bests-physician-s-choice-for-brca-mcrpc"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0583"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.5005"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2681674","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2026.2681674","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2681674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T07:10:57Z","timestamp":1787123457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2026.2681674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":53,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,6,21]]}},"alternative-id":["10.1080\/14796694.2026.2681674"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2026.2681674","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}